![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://www.cell.com/cms/10.1016/j.xcrm.2025.102511/asset/5f59431a-fe0c-481f-b78f-cfc75897fa34/main.assets/gr1_lrg.jpg)
glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]
Description
Importantly, as shown in a subset of patients, no significant cross-reaction was observed between anti-exenatide antibodies and human GLP-1 or glucagon
![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
Ageing Res Rev (2019) 54:100936
![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://www.spandidos-publications.com/article_images/ijmm/48/6/IJMM-48-06-05052-g02.jpg)
The employer benefits too, because carriers offer discounts to companies that can show they are actively investing in workforce health, the same way they do with smoking cessation programs
![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://assets.medpagetoday.net/media/images/118xxx/118973.jpg?width=0.8)
10.1158/1535-7163.Mct-10-0318 15 ButA.De BruinM
![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://neurologytoday.aan.com/cms/10.1097/01.wnt.0001181068.69552.5a/asset/37ea394f-4f55-44bd-a241-2abc4fb14105/assets/graphic/keyimage.jpg)
e1 (2022)
![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-024-03412-w/MediaObjects/41591_2024_3412_Fig1_HTML.png)
Study uncovers how chronic kidney disease impacts glucose and glycemic control (SACRAMENTO) A new collaborative study from researchers at UC Davis Health and the UC Davis School of Veterinary Medicine reveals how complications from chronic kidney disease (CKD) are linked to problems in the metabolic system
![glp-1 and seizures Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine glp-1_analogs [TUSOM | Pharmwiki]](https://ajbps.org/content/138/2026/6/1/img/AJBPS-6-1-g001.png)
